AU2021325339A1 - SARS-CoV-2 antibodies for treatment and prevention of COVID-19 - Google Patents
SARS-CoV-2 antibodies for treatment and prevention of COVID-19 Download PDFInfo
- Publication number
- AU2021325339A1 AU2021325339A1 AU2021325339A AU2021325339A AU2021325339A1 AU 2021325339 A1 AU2021325339 A1 AU 2021325339A1 AU 2021325339 A AU2021325339 A AU 2021325339A AU 2021325339 A AU2021325339 A AU 2021325339A AU 2021325339 A1 AU2021325339 A1 AU 2021325339A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063862P | 2020-08-10 | 2020-08-10 | |
| US63/063,862 | 2020-08-10 | ||
| US202063112104P | 2020-11-10 | 2020-11-10 | |
| US63/112,104 | 2020-11-10 | ||
| PCT/EP2021/072203 WO2022034044A1 (en) | 2020-08-10 | 2021-08-09 | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021325339A1 true AU2021325339A1 (en) | 2023-04-06 |
Family
ID=77595513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021325339A Abandoned AU2021325339A1 (en) | 2020-08-10 | 2021-08-09 | SARS-CoV-2 antibodies for treatment and prevention of COVID-19 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220041694A1 (https=) |
| EP (1) | EP4192860A1 (https=) |
| JP (1) | JP2023537078A (https=) |
| KR (1) | KR20230045613A (https=) |
| CN (1) | CN116234577A (https=) |
| AU (1) | AU2021325339A1 (https=) |
| BR (1) | BR112023002234A2 (https=) |
| CA (1) | CA3190280A1 (https=) |
| IL (1) | IL300257A (https=) |
| TW (1) | TW202221025A (https=) |
| WO (1) | WO2022034044A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4045533T3 (fi) | 2020-03-26 | 2024-02-02 | Univ Vanderbilt | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| JP2025514858A (ja) | 2022-04-29 | 2025-05-09 | アストラゼネカ・ユーケイ・リミテッド | ＳＡＲＳ－ＣｏＶ－２抗体、及びその使用方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| CA2478297C (en) | 2002-03-19 | 2013-05-14 | Plant Research International B.V. | Optimizing glycan processing in plants |
| CN103540600B (zh) | 2003-01-22 | 2017-12-01 | 罗氏格黎卡特股份公司 | 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途 |
| JP2008539753A (ja) | 2005-05-09 | 2008-11-20 | グリクアート バイオテクノロジー アクチェンゲゼルシャフト | 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子 |
| BRPI0707290A2 (pt) | 2006-01-17 | 2011-08-16 | Biolex Therapeutics Inc | composições e métodos para humanização e otimização de n-glicanas em plantas |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| CN104119438A (zh) | 2009-01-29 | 2014-10-29 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| RU2017107847A (ru) * | 2014-09-03 | 2018-10-03 | Медиммун Лимитед | Стабильный состав на основе антитела к il-4r-альфа |
| FI4045533T3 (fi) * | 2020-03-26 | 2024-02-02 | Univ Vanderbilt | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) |
| AU2021275361A1 (en) * | 2020-05-17 | 2023-01-19 | Astrazeneca Uk Limited | SARS-CoV-2 antibodies and methods of selecting and using the same |
-
2021
- 2021-08-09 AU AU2021325339A patent/AU2021325339A1/en not_active Abandoned
- 2021-08-09 CN CN202180056725.0A patent/CN116234577A/zh active Pending
- 2021-08-09 WO PCT/EP2021/072203 patent/WO2022034044A1/en not_active Ceased
- 2021-08-09 CA CA3190280A patent/CA3190280A1/en active Pending
- 2021-08-09 EP EP21763274.4A patent/EP4192860A1/en active Pending
- 2021-08-09 BR BR112023002234A patent/BR112023002234A2/pt unknown
- 2021-08-09 TW TW110129325A patent/TW202221025A/zh unknown
- 2021-08-09 JP JP2023509418A patent/JP2023537078A/ja active Pending
- 2021-08-09 IL IL300257A patent/IL300257A/en unknown
- 2021-08-09 KR KR1020237008224A patent/KR20230045613A/ko active Pending
- 2021-08-09 US US17/397,203 patent/US20220041694A1/en not_active Abandoned
-
2023
- 2023-08-09 US US18/446,782 patent/US20240092875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL300257A (en) | 2023-03-01 |
| US20240092875A1 (en) | 2024-03-21 |
| CN116234577A (zh) | 2023-06-06 |
| CA3190280A1 (en) | 2022-02-17 |
| WO2022034044A1 (en) | 2022-02-17 |
| JP2023537078A (ja) | 2023-08-30 |
| US20220041694A1 (en) | 2022-02-10 |
| EP4192860A1 (en) | 2023-06-14 |
| KR20230045613A (ko) | 2023-04-04 |
| TW202221025A (zh) | 2022-06-01 |
| BR112023002234A2 (pt) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240182548A1 (en) | Sars-cov-2 antibodies and methods of selecting and using the same | |
| KR102876923B1 (ko) | 항-il-2 항체 및 조성물 및 이의 용도 | |
| DK2831113T3 (en) | ANTIBODIES AGAINST BRADYKININ-B1 RECEPTOR LIGANDS | |
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| EP4124624A2 (en) | Antibodies against canine pd-1 | |
| EP4041763B1 (en) | Pd1 and vegfr2 dual-binding agents | |
| AU2022256455A1 (en) | Anti-cd122 antibodies and uses thereof | |
| US20230242626A1 (en) | Composition for treatment and prevention of covid-19 | |
| JP2025166101A (ja) | 新規抗Ｎｏｇｏ－Ａ抗体 | |
| EP4514842B1 (en) | Sars-cov-2 antibodies and methods of using the same | |
| EA052645B1 (ru) | Композиция для лечения и предупреждения covid-19 | |
| JP2025523477A (ja) | インテグリンアルファ１１ベータ１に対する抗体及びその使用 | |
| HK40075900B (en) | Pd1 and vegfr2 dual-binding agents | |
| HK40075900A (en) | Pd1 and vegfr2 dual-binding agents | |
| CN117120092A (zh) | 用于治疗儿科重症肌无力的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |